Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
View Patent ↗The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
1. A method for determining a prognosis of a patient with chronic lymphocytic leukemia (CLL) comprising:
(a) obtaining a biological sample of the patient comprising lymphocytes;
(b) determining the sample expression level of phosphodiesterase 7B (PDE7B);
(c) comparing the expression level of PDE7B in the patient sample relative to a baseline expression level of said PDE7B; and
(d) associating a higher relative patient PDE7B expression level with a higher risk course of CLL, thereby determining the prognosis of the patient with CLL.
2. The method of claim 1 , wherein said PDE7B expression level comprises a PDE7B mRNA expression level or a PDE7B protein expression level.
3. The method of claim 2 , wherein said PDE7B mRNA expression level in said patient is about 5-70 fold higher than the baseline expression level.
4. The method of claim 2 , wherein said PDE7B protein expression level in said patient is about 5-90 fold higher than the baseline expression level.
5. The method of claim 1 , wherein said lymphocytes comprise peripheral blood mononuclear cells (PBMCs) or B cells.
6. A kit for determining a prognosis of a patient with CLL comprising biomarker detecting reagents for detecting expression level of phosphodiesterase 7B (PDE7B) in lymphocytes from said patient, and instructions for determining the prognosis of said patient's CLL by comparing the expression level of PDE7B in the patient sample relative to a baseline expression level of said PDE7B and associating a higher relative patient PDE7B expression level with a higher risk course of CCL, thereby determining the prognosis of the patient with CLL.
7. The kit of claim 6 , wherein said expression level of PDE7B comprises a PDE7B mRNA expression level or a PDE7B protein expression level.
8. The kit of claim 7 , wherein said PDE7B mRNA expression level in said patient is about 5-70 fold higher than the baseline expression level.
9. The kit of claim 7 , wherein said PDE7B protein expression level in said patient is about 5-90 fold higher than the baseline expression level.
10. The kit of claim 6 , wherein said lymphocytes comprises peripheral blood mononuclear cells (PBMCs) or B cells.